The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Shaun G. Goodman

St Michael's Hospital and University of Toronto

Toronto

Ontario

[email]@smh.toronto.on.ca

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • St Michael's Hospital and University of Toronto, Toronto, Ontario. 1996 - 2010
  • Canadian Heart Research Centre and Terrence Donnelly Heart Centre, Division of Cardiology, St. Michael's Hospital, University of Toronto, Canada. 1998 - 2009
  • St. Michael's Hospital, Division of Cardiology, 30 Bond Street, Queen, Canada. 2008
  • St. Michael's Hospital, Toronto, Ontario, Canada. 2005

References

  1. Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Goodman, S.G., Langer, A., Bastien, N.R., McPherson, R., Francis, G.A., Genest, J.J., Leiter, L.A. Can. J. Cardiol (2010) [Pubmed]
  2. The expanded Global Registry of Acute Coronary Events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. Goodman, S.G., Huang, W., Yan, A.T., Budaj, A., Kennelly, B.M., Gore, J.M., Fox, K.A., Goldberg, R.J., Anderson, F.A. Am. Heart J. (2009) [Pubmed]
  3. Drip-and-ship for acute ST-segment myocardial infarction: the pharmacoinvasive strategy for patients treated with fibrinolytic therapy. Goodman, S.G., Cantor, W.J. Pol. Arch. Med. Wewn. (2009) [Pubmed]
  4. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Goodman, S.G., Menon, V., Cannon, C.P., Steg, G., Ohman, E.M., Harrington, R.A. Chest (2008) [Pubmed]
  5. The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience. Goodman, S.G., Fu, Y., Langer, A., Barr, A., Tan, M., Wagner, G.S., Barbagelata, A., Sgarbossa, E.B., Birnbaum, Y., Granger, C.B., Califf, R.M., Van de Werf, F., Topol, E.J., Armstrong, P.W. Am. Heart J. (2006) [Pubmed]
  6. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). Goodman, S.G., Steg, P.G., Eagle, K.A., Fox, K.A., López-Sendón, J., Montalescot, G., Budaj, A., Kennelly, B.M., Gore, J.M., Allegrone, J., Granger, C.B., Gurfinkel, E.P. Am. Heart J. (2006) [Pubmed]
  7. The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy. Goodman, S.G., Bozovich, G.E., Tan, M., Dos Santos, A., Gurfinkel, E.P., Cohen, M., Langer, A. Am. Heart J. (2006) [Pubmed]
  8. Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial. Goodman, S. Am. Heart J. (2005) [Pubmed]
  9. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Goodman, S.G., Fitchett, D., Armstrong, P.W., Tan, M., Langer, A. Circulation (2003) [Pubmed]
  10. Development and prognosis of non-Q-wave myocardial infarction in the thrombolytic era. Goodman, S.G., Barr, A., Langer, A., Wagner, G.S., Fitchett, D., Armstrong, P.W., Naylor, C.D. Am. Heart J. (2002) [Pubmed]
  11. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. Goodman, S.G., Cohen, M., Bigonzi, F., Gurfinkel, E.P., Radley, D.R., Le Iouer, V., Fromell, G.J., Demers, C., Turpie, A.G., Califf, R.M., Fox, K.A., Langer, A. J. Am. Coll. Cardiol. (2000) [Pubmed]
  12. Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy. Goodman, S.G., Barr, A., Sobtchouk, A., Cohen, M., Fromell, G.J., Laperrière, L., Hill, C., Langer, A. J. Am. Coll. Cardiol. (2000) [Pubmed]
  13. Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators. Goodman, S.G., Langer, A., Ross, A.M., Wildermann, N.M., Barbagelata, A., Sgarbossa, E.B., Wagner, G.S., Granger, C.B., Califf, R.M., Topol, E.J., Simoons, M.L., Armstrong, P.W. Circulation (1998) [Pubmed]
  14. PROTECT (Prospective Reinfarction Outcomes in the Thrombolytic Era Cardizem CD Trial): a randomized, double-blind clinical trial of diltiazem versus atenolol in secondary prophylaxis post non-Q wave myocardial infarction. Goodman, S., Hill, C., Bata, I., Fung, A., Higginson, L., Lam, J., Massel, D., McCans, J., Nasmith, J., Stanton, E., Thompson, C., Warnica, W., Langer, A. Can. J. Cardiol (1996) [Pubmed]
 
WikiGenes - Universities